IND-enabling studies to develop triptonide into the first nonhormonal male pill
Ended Project Grant Awarded Last action
- Award ID
- R61HD114186
- Recipient
-
Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center UEI LTJVF4QSFCP9
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,013,624
Award facts
- Assistance listing
- 93.865 Child Health and Human Development Extramural Research
- Completion date
- Place of performance
- Torrance, CA 90502, USA
Award details come from USAspending.gov.
Description
- Abstract
- Our twelve years of research has led to the discovery of triptonide (TN) as a promising non- hormonal male contraceptive agent (nature communications, 2021, 12:1253). In addition to its excellent potency and proven oral bioavailability, TN does not cause discernable toxic effects in either mice or monkeys at its minimum effective dose. All available data strongly suggest that TN is worth further investment to develop IT as a viable non-hormonal male contraceptive drug candidate. Taking advantage of the R61/R33 funding mechanism, we propose to conduct several investigational new drug (IND)-enabling studies to collect data required by the FDA for official IND application. Specifically, we will conduct non-GLP toxicity and safety pharmacology studies to identify the maximum tolerated dose (MTD) followed by a six-month repeat dose toxicity study using MTD and minimum effective doses (MED) in male sprague-dawley rats in the R61 phase. In addition, deep learning-based pathological and RNA-SEQ-based transcriptomic analyses will also be performed. The data will not only guide and corroborate the GLP-compliant toxicity and safety pharmacology studies proposed in the R33 phase, but also provide molecular insights for any potential phenotypes observed. In the R33 phase, we will work with pharmaron INC. To perform non-GLP toxicity studies in dogs, in vitro secondary pharmacology, and GLP-compliant repeat-dose toxicity and safety pharmacology studies all as part of a package of studies intended to move triptonide into a phase i clinical trial.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $341,600 | |
| Amendment | -$318,099 | |
| Amendment | $341,600 | |
| Amendment | -$318,099 | |
| Amendment | $341,600 | |
| Amendment | -$318,099 | |
| Amendment | $35,344 | |
| Amendment | $35,344 | |
| Amendment | $35,344 | |
| Amendment | $35,344 | |
| Amendment | $318,099 | |
| Amendment | $318,099 | |
| Amendment | $318,099 | |
| Amendment | $318,099 | |
| Amendment | $318,099 | |
| Amendment | $403,750 | |
| Amendment | $403,750 | |
| Original award | $403,750 |
Show all 21
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Contraceptive Accelerator Network, LLC | $20,000 |
Quick answers
Who received award R61HD114186?
R61HD114186 was awarded to Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center by National Institute of Child Health and Human Development (National Institutes of Health) on February 1, 2024.
How much is award R61HD114186 worth?
$3,013,624 has been obligated on R61HD114186.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award